Company / Shareholders' Equity
AXIM BIOTECHNOLOGIES, INC. Shareholders' Equity History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$7.7M
FY2023
5-year range
-$7.7M / -$2.4M
FY2019-FY2023
Trend
-58.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
AXIM BIOTECHNOLOGIES, INC. reports negative total equity of -$8M in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$8M in FY2023.
Declined from -$6M to -$8M over the past 5 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, shareholders' equity decreased 58.7% year-over-year.
- Peak shareholders' equity was recorded in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$7.7M | -58.7% |
| FY2022 | -$4.8M | +20.7% |
| FY2018 | -$6.1M | +3.2% |
| FY2017 | -$6.3M | -165.0% |
| FY2016 | -$2.4M | -39.9% |
| FY2015 | -$1.7M | -1705.0% |
| FY2013 | -$93.9K | -1899.1% |
| FY2012 | -$4.7K | -146.0% |
| FY2011 | $10.2K | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026